BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALVEY (talquetamab) is a bispecific antibody (BSAB) approved by the FDA in August 2023 for relapsed or refractory multiple myeloma. It targets both CD3 on T cells and GPRC5D on myeloma cells, enabling dual-targeting immunotherapy. The mechanism engages the patient's own immune system to recognize and eliminate myeloma cells.
Growth
Early-stage launch in a high-value oncology indication with aggressive competitive pressure (30/100), creating demand for field-based and market access roles to establish market position.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Started Dec 2025
25 enrolled
Relapsed Refractory Multiple Myeloma (RRMM)
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Started Dec 2025
150 enrolled
Multiple Myeloma (MM)
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Started Nov 2025
23 enrolled
Multiple Myeloma in Relapse
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Started Jul 2025
32 enrolled
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Started Jun 2025
20 enrolled
Multiple MyelomaPost Stem Cell Transplant
Worked on TALVEY at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.